Susquehanna International Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-24,000
| Closed | -$12.7K | – | 13883 |
|
|
2022
Q4 | $12.7K | Sell |
24,000
-2,500
| -9% | -$1.59K | ﹤0.01% | 11885 |
|
|
2022
Q3 | $19K | Buy |
26,500
+1,100
| +4% | +$1.25K | ﹤0.01% | 12624 |
|
|
2022
Q2 | $29K | Sell |
25,400
-2,400
| -9% | -$3.06K | ﹤0.01% | 12245 |
|
|
2022
Q1 | $57K | Sell |
27,800
-19,100
| -41% | -$45.4K | ﹤0.01% | 12257 |
|
|
2021
Q4 | $135K | Sell |
46,900
-154,900
| -77% | -$573K | ﹤0.01% | 11912 |
|
|
2021
Q3 | $856K | Sell |
201,800
-153,300
| -43% | -$684K | ﹤0.01% | 7973 |
|
|
2021
Q2 | $1.88M | Sell |
355,100
-217,800
| -38% | -$1.05M | ﹤0.01% | 6058 |
|
|
2021
Q1 | $2.66M | Buy |
572,900
+369,200
| +181% | +$1.67M | ﹤0.01% | 5232 |
|
|
2020
Q4 | $672K | Buy |
203,700
+18,200
| +10% | +$69.1K | ﹤0.01% | 7635 |
|
|
2020
Q3 | $614K | Sell |
185,500
-77,000
| -29% | -$283K | ﹤0.01% | 7248 |
|
|
2020
Q2 | $885K | Buy |
262,500
+138,500
| +112% | +$655K | ﹤0.01% | 6188 |
|
|
2020
Q1 | $475K | Sell |
124,000
-82,300
| -40% | -$382K | ﹤0.01% | 7056 |
|
|
2019
Q4 | $1.25M | Sell |
206,300
-96,200
| -32% | -$658K | ﹤0.01% | 5107 |
|
|
2019
Q3 | $2.29M | Sell |
302,500
-449,500
| -60% | -$5.07M | ﹤0.01% | 3933 |
|
|
2019
Q2 | $10.2M | Buy |
752,000
+670,200
| +819% | +$7.74M | ﹤0.01% | 1864 |
|
|
2019
Q1 | $443K | Buy |
+81,800
| New | +$398K | ﹤0.01% | 6507 |
|
|
2018
Q4 | – | Sell |
-46,500
| Closed | -$379K | – | 10229 |
|
|
2018
Q3 | $379K | Sell |
46,500
-3,500
| -7% | -$26.9K | ﹤0.01% | 7017 |
|
|
2018
Q2 | $487K | Buy |
50,000
+25,000
| +100% | +$256K | ﹤0.01% | 6846 |
|
|
2018
Q1 | $217K | Sell |
25,000
-39,600
| -61% | -$427K | ﹤0.01% | 8198 |
|
|
2017
Q4 | $809K | Sell |
64,600
-423,800
| -87% | -$4.86M | ﹤0.01% | 5667 |
|
|
2017
Q3 | $4.08M | Buy |
488,400
+53,000
| +12% | +$560K | ﹤0.01% | 2778 |
|
|
2017
Q2 | $7.39M | Buy |
435,400
+289,700
| +199% | +$5.76M | ﹤0.01% | 1965 |
|
|
2017
Q1 | $2.93M | Buy |
145,700
+85,200
| +141% | +$1.69M | ﹤0.01% | 3073 |
|
|
2016
Q4 | $943K | Buy |
+60,500
| New | +$815K | ﹤0.01% | 5657 |
|
Susquehanna International Group's ZYNE Position: Q4 2023 in Review
Susquehanna International Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 221,719 shares — an estimated $282K sold.
Susquehanna International Group first reported a position in ZYNE in Q4 2017 and held it in 18 quarters. The position peaked at $2.69M in Q3 2018. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Susquehanna International Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Susquehanna International Group sold 221,719 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $282K.
- Susquehanna International Group first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 18 quarters.
- Susquehanna International Group's Zynerba Pharmaceuticals, Inc position peaked at $2.69M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.